Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65

Author(s): J. Fraser Wright, Jennifer Wellman, Katherine A. High

Journal Name: Current Gene Therapy

Volume 10 , Issue 5 , 2010

Become EABM
Become Reviewer
Call for Editor


Recombinant adeno-associated virus (AAV) -based vectors expressing therapeutic gene products have shown great promise for human gene therapy. A recent milestone has been the safety and efficacy observed using recombinant AAV2 expressing retinal pigment epithelial associated 65KDa protein for Leber Congenital Amaurosis. This review summarizes manufacturing and characterization of ‘AAV2-hRPE65v2’, the vector used in one completed Phase I/II clinical trial. Regulatory challenges and strategies that were successfully used for this groundbreaking trial are described.

Keywords: AAV vectors, regulatory affairs, cGMP, Leber Congenital Amaurosis, AAV2-hRPE65v2, LCA, Adeno associated virus, RPE65, gene therapy, electroretinograms, alpha1-antitryspin deficiency, Alzheimer's disease, arthritis, Batten's disease, Canavan's disease, cystic fibrosis, Hemophilia B, HIV infection, Parkinson's disease, muscular dystrophy, prostate cancer, malignant melanoma, HEPA, cation exchange column chromatography, HEK293, CRUDE CELL HARVEST, ampicillin, reverse transcriptase Q-PCR, Column chromatography

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Published on: 01 March, 2012
Page: [341 - 349]
Pages: 9
DOI: 10.2174/156652310793180715

Article Metrics

PDF: 131